PainChek hits over four-month high on expanded Sabra agreement uptake
SBRA•PainChek shares rose as much as 41.4% to A$0.140 after expanded commercial uptake under its agreement with Sabra Health Care REIT extended its reach to 23 US communities across five operators.
1. Expanded US footprint
PainChek said expanded commercial uptake under its master services agreement with Sabra Health Care REIT brings its footprint to 23 US communities across five operators. Its shares rose as much as 41.4% to A$0.140, their highest since June 4, while about 1.1 million shares traded, nearly 9.7 times the 30-day average.
